UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
A rare missense variant in FRS3 associates with lower body mass index and protection against obesity
Scientists at deCODE genetics, a subsidiary of Amgen, and collaborators have published a study in Nature Communications reporting a rare missense variant in FRS3 that associates with decreased body mass index (BMI) and protection against obesity. This missense variant was discovered in a meta-analysis of genome-wide association studies that included 2 million individuals of diverse ancestries.
Rare loss-of-function variants in HECTD2 and AKAP11 confer a risk of bipolar disorder
Scientists at deCODE genetics, a subsidiary of Amgen, reveal today in Nature Genetics, associations between rare loss-of-function variants in two genes and bipolar disorder.
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.